Effect of chemotherapy for the dysmyelopoietic syndrome

James Olen Armitage, F. R. Dick, S. W. Needleman, C. P. Burns

Research output: Contribution to journalArticle

92 Citations (Scopus)

Abstract

Twenty patients are described who received chemotherapy for the diagnosis of acute myeloid leukemia but who were subsequently reclassified as having dysmyelopoietic syndrome using the French-American-British criteria. Thirteen patients had refractory anemia with excess blast cells (RAEB) (age range, 23-82 years; median, 68) and seven had chronic myelomonocytic leukemia (CMML) (age range, 44-79 years; median, 70). Three patients (two with RAEB and one with chronic myelomonocytic leukemia) had previously been treated with cytotoxic therapy for another malignancy. In 15 patients the antileukemic therapy was a chemotherapy regimen that was highly active in acute nonlymphoblastic leukemia (ie, containing daunorubicin and/or cytarabine). These patients achieved complete remission lasting 14, 34+, and 36+ months and survival times of 31, 35+, and 37+ months. All three patients were from a subgroup of four patients characterized by RAEB, younger age, no previous cytotoxic therapy, and treatment with an aggressive chemotherapy regimen. The median survival time of the patients not achieving remission was 1 month (range, < 1-22). Our results suggest that while most patients with the dysmyelopoietic syndrome appear to have their life shortened by chemotherapy, there is a subgroup characterized by younger age, absence of previous cytotoxic therapy, and the morphologic picture of RAEB who can have a favorable response to aggressive treatment.

Original languageEnglish (US)
Pages (from-to)601-605
Number of pages5
JournalCancer Treatment Reports
Volume65
Issue number7-8
StatePublished - Jan 1 1981

Fingerprint

Myelodysplastic Syndromes
Drug Therapy
Refractory Anemia with Excess of Blasts
Leukemia, Myelomonocytic, Chronic
Acute Myeloid Leukemia
Therapeutics
Daunorubicin
Survival
Cytarabine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Armitage, J. O., Dick, F. R., Needleman, S. W., & Burns, C. P. (1981). Effect of chemotherapy for the dysmyelopoietic syndrome. Cancer Treatment Reports, 65(7-8), 601-605.

Effect of chemotherapy for the dysmyelopoietic syndrome. / Armitage, James Olen; Dick, F. R.; Needleman, S. W.; Burns, C. P.

In: Cancer Treatment Reports, Vol. 65, No. 7-8, 01.01.1981, p. 601-605.

Research output: Contribution to journalArticle

Armitage, JO, Dick, FR, Needleman, SW & Burns, CP 1981, 'Effect of chemotherapy for the dysmyelopoietic syndrome', Cancer Treatment Reports, vol. 65, no. 7-8, pp. 601-605.
Armitage JO, Dick FR, Needleman SW, Burns CP. Effect of chemotherapy for the dysmyelopoietic syndrome. Cancer Treatment Reports. 1981 Jan 1;65(7-8):601-605.
Armitage, James Olen ; Dick, F. R. ; Needleman, S. W. ; Burns, C. P. / Effect of chemotherapy for the dysmyelopoietic syndrome. In: Cancer Treatment Reports. 1981 ; Vol. 65, No. 7-8. pp. 601-605.
@article{9d771276bb2e4679bea2554d7d1b272c,
title = "Effect of chemotherapy for the dysmyelopoietic syndrome",
abstract = "Twenty patients are described who received chemotherapy for the diagnosis of acute myeloid leukemia but who were subsequently reclassified as having dysmyelopoietic syndrome using the French-American-British criteria. Thirteen patients had refractory anemia with excess blast cells (RAEB) (age range, 23-82 years; median, 68) and seven had chronic myelomonocytic leukemia (CMML) (age range, 44-79 years; median, 70). Three patients (two with RAEB and one with chronic myelomonocytic leukemia) had previously been treated with cytotoxic therapy for another malignancy. In 15 patients the antileukemic therapy was a chemotherapy regimen that was highly active in acute nonlymphoblastic leukemia (ie, containing daunorubicin and/or cytarabine). These patients achieved complete remission lasting 14, 34+, and 36+ months and survival times of 31, 35+, and 37+ months. All three patients were from a subgroup of four patients characterized by RAEB, younger age, no previous cytotoxic therapy, and treatment with an aggressive chemotherapy regimen. The median survival time of the patients not achieving remission was 1 month (range, < 1-22). Our results suggest that while most patients with the dysmyelopoietic syndrome appear to have their life shortened by chemotherapy, there is a subgroup characterized by younger age, absence of previous cytotoxic therapy, and the morphologic picture of RAEB who can have a favorable response to aggressive treatment.",
author = "Armitage, {James Olen} and Dick, {F. R.} and Needleman, {S. W.} and Burns, {C. P.}",
year = "1981",
month = "1",
day = "1",
language = "English (US)",
volume = "65",
pages = "601--605",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "7-8",

}

TY - JOUR

T1 - Effect of chemotherapy for the dysmyelopoietic syndrome

AU - Armitage, James Olen

AU - Dick, F. R.

AU - Needleman, S. W.

AU - Burns, C. P.

PY - 1981/1/1

Y1 - 1981/1/1

N2 - Twenty patients are described who received chemotherapy for the diagnosis of acute myeloid leukemia but who were subsequently reclassified as having dysmyelopoietic syndrome using the French-American-British criteria. Thirteen patients had refractory anemia with excess blast cells (RAEB) (age range, 23-82 years; median, 68) and seven had chronic myelomonocytic leukemia (CMML) (age range, 44-79 years; median, 70). Three patients (two with RAEB and one with chronic myelomonocytic leukemia) had previously been treated with cytotoxic therapy for another malignancy. In 15 patients the antileukemic therapy was a chemotherapy regimen that was highly active in acute nonlymphoblastic leukemia (ie, containing daunorubicin and/or cytarabine). These patients achieved complete remission lasting 14, 34+, and 36+ months and survival times of 31, 35+, and 37+ months. All three patients were from a subgroup of four patients characterized by RAEB, younger age, no previous cytotoxic therapy, and treatment with an aggressive chemotherapy regimen. The median survival time of the patients not achieving remission was 1 month (range, < 1-22). Our results suggest that while most patients with the dysmyelopoietic syndrome appear to have their life shortened by chemotherapy, there is a subgroup characterized by younger age, absence of previous cytotoxic therapy, and the morphologic picture of RAEB who can have a favorable response to aggressive treatment.

AB - Twenty patients are described who received chemotherapy for the diagnosis of acute myeloid leukemia but who were subsequently reclassified as having dysmyelopoietic syndrome using the French-American-British criteria. Thirteen patients had refractory anemia with excess blast cells (RAEB) (age range, 23-82 years; median, 68) and seven had chronic myelomonocytic leukemia (CMML) (age range, 44-79 years; median, 70). Three patients (two with RAEB and one with chronic myelomonocytic leukemia) had previously been treated with cytotoxic therapy for another malignancy. In 15 patients the antileukemic therapy was a chemotherapy regimen that was highly active in acute nonlymphoblastic leukemia (ie, containing daunorubicin and/or cytarabine). These patients achieved complete remission lasting 14, 34+, and 36+ months and survival times of 31, 35+, and 37+ months. All three patients were from a subgroup of four patients characterized by RAEB, younger age, no previous cytotoxic therapy, and treatment with an aggressive chemotherapy regimen. The median survival time of the patients not achieving remission was 1 month (range, < 1-22). Our results suggest that while most patients with the dysmyelopoietic syndrome appear to have their life shortened by chemotherapy, there is a subgroup characterized by younger age, absence of previous cytotoxic therapy, and the morphologic picture of RAEB who can have a favorable response to aggressive treatment.

UR - http://www.scopus.com/inward/record.url?scp=0019493760&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019493760&partnerID=8YFLogxK

M3 - Article

VL - 65

SP - 601

EP - 605

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 7-8

ER -